Indaptus Therapeutics, Inc. 8-K

What Happened

• Indaptus Therapeutics, Inc. filed an 8-K on January 2, 2026 reporting that on December 29, 2025 three members of its Board of Directors — Michael Newman, Mark Gilbert, and Anthony Maddaluna — notified the company they will resign from the Board.
• The resignations become effective upon the approval of nominees put forward by David Lazar at the company’s next stockholders’ meeting. The filing states the resignations were not due to any disagreement with the company, its management, the Board, or any committee.

Key Details

• Three directors notified resignations: Michael Newman, Mark Gilbert, Anthony Maddaluna.
• Notice given on December 29, 2025; 8-K filed January 2, 2026.
• Resignations effective upon approval of David Lazar’s nominees at the next stockholders’ meeting.
• Filing explicitly states resignations were not the result of any disagreement with management or the Board.

Why It Matters

• These resignations will change the company’s Board composition once David Lazar’s nominees are approved, which affects corporate governance and who oversees strategy and management.
• Investors should watch for proxy materials, the announced date of the stockholders’ meeting, and any additional 8-Ks or filings that disclose the nominee slate and final Board makeup.